Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib with Docetaxel in NSCLC
NCT02451865Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events, Incidence of dose-limiting toxicities at 21 days and 1 more. Planned start Jun 2016; status: withdrawn.
02
Drugs
binimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02451865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451865.